Human trials, positive results. More results on existing pipeline would probably be a small move but not significant. When they show their flu drug candidate is effective against most if not all strains including the new, mutating China virus, people will be pounding the table for the FDA to focus and get this into the market. The company won't see a big increase in pps until the public knows their drug(s) work and they are coming to and/or are in the market. Even if they aren't in the market in the US yet but on their way.
To help, the new facility is being completed so they are moving in the right direction. When it is completed, it will be an additional sign that this is a company, although initially small, moving toward being fully functional and competitive. Obviously, this will not be overnight and we will continue to be frustrated with the process.
News 
Market Data 
Discover 
AI
